TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Tropomyosin-related kinase C (TrkC) is a neurotrophin receptor involved in cancer growth and metastasis.
• TrkC functions as an active protein tyrosine kinase, often overexpressed in tumors.
• Bone morphogenetic protein 2 (BMP-2) is known to have tumor-suppressive activities.

Purpose of the Study:

• To investigate the interaction between TrkC and BMP-2 signaling pathways.
• To elucidate the mechanism by which TrkC influences BMP-2-induced cellular responses.
• To determine if TrkC modulates the tumor-suppressive activity of BMP-2.

Main Methods:

• Utilized small interfering RNA (siRNA) to silence TrkC expression in CT26 colon cancer cells.
• Assessed BMP-2-induced Smad1 phosphorylation and transcriptional activation.
• Investigated the direct binding of TrkC to BMP type II receptor (BMPRII) using co-immunoprecipitation assays.
• Expressed TrkC in RIE-1 cells to evaluate its effect on BMP-2 signaling.

Main Results:

• TrkC expression suppressed BMP-2-induced Smad1 phosphorylation and transcriptional activation.
• Silencing TrkC in CT26 cells enhanced BMP-2 signaling and restored its growth inhibitory effects.
• TrkC directly binds to BMPRII, preventing its interaction with BMPRI, a process dependent on TrkC kinase activity.
• TrkC expression in RIE-1 cells completely inhibited BMP-2 transcriptional activation.

Conclusions:

• TrkC acts as an inhibitor of BMP-2 tumor-suppressor activity through direct interaction with BMPRII.
• This interaction blocks BMP-2 signaling, contributing to cancer progression.
• TrkC represents a novel therapeutic target for cancers where BMP-2 signaling is dysregulated.